LTRN Lantern Pharma Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1763950 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY27.2%
TTM EPS YoY17.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-250.6%
ROA-124.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets83.5%
Debt / equity0.00x
Current ratio1.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.57M | $1.79M | $1.72M | $2.74M | $2.44M | $3.07M | $3.26M | $4.27M |
| SG&A expense | $3.81M | $1.72M | $1.68M | $1.46M | $1.91M | $1.58M | $1.51M | $1.63M |
| Operating income | -$5.38M | -$3.51M | -$3.41M | -$4.20M | -$4.35M | -$4.65M | -$4.77M | -$5.90M |
| Net income | $696,615 | -$7.07M | -$3.33M | -$4.07M | -$4.18M | -$4.33M | -$4.54M | -$5.88M |
| EBITDA | -$5.37M | -$3.50M | -$3.40M | -$4.20M | -$4.35M | -$4.65M | -$4.77M | -$5.89M |
| EPS (basic) | 0.05 | -0.57 | -0.30 | — | -0.39 | -0.40 | -0.42 | — |
| EPS (diluted) | -0.37 | -0.57 | -0.30 | — | -0.39 | -0.40 | -0.42 | — |
| Weighted avg. shares (diluted) | 13.63M | 12.42M | 11.25M | — | 10.83M | 10.78M | 10.78M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.62M | $6.66M | $4.92M | $4.42M | $8.39M | $6.06M | $6.38M | $7.51M |
| Short-term investments | $10,882 | $701,085 | $1.41M | $5.70M | $3.97M | $9.84M | $13.34M | $16.50M |
| Current assets | $8.41M | $8.46M | $7.06M | $10.80M | $13.46M | $17.20M | $20.82M | $25.25M |
| PP&E, net | $20,789 | $24,271 | $28,022 | $31,875 | $35,977 | $39,524 | $44,025 | $47,440 |
| Total assets | $8.52M | $8.60M | $7.22M | $11.04M | $13.63M | $17.42M | $21.10M | $25.57M |
| Current liabilities | $5.65M | $4.32M | $3.78M | $4.50M | $4.04M | $4.88M | $4.29M | $4.33M |
| Total liabilities | $7.11M | $11.82M | $3.78M | $4.50M | $4.04M | $4.90M | $4.32M | $4.38M |
| Shareholders' equity | $1.41M | -$3.22M | $3.45M | $6.53M | $9.59M | $12.52M | $16.78M | $21.19M |
| Shares outstanding | 14.94M | 12.76M | 11.25M | 11.25M | 11.04M | 10.78M | 10.78M | 10.78M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.34M | -$2.94M | -$3.77M | -$2.79M | -$4.57M | -$3.94M | -$4.38M | -$3.97M |
| Capital expenditure | — | — | — | $1 | $555 | $0 | $1,159 | $3,083 |
| Free cash flow | — | — | — | -$2.79M | -$4.57M | -$3.94M | -$4.38M | -$3.97M |
| Investing cash flow | $672,037 | $692,250 | $4.25M | -$1.70M | $5.93M | $3.59M | $3.24M | $3.45M |
| Financing cash flow | $3.63M | — | — | $526,459 | — | — | — | $0 |
| Depreciation & amortization | $3,482 | $3,751 | $3,853 | $4,103 | $4,102 | $4,501 | $4,574 | $4,574 |
| Stock-based compensation | $229,550 | — | — | $198,939 | $143,685 | $160,626 | $147,750 | $204,606 |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.